Correction to “Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA”

Documenti analoghi

• Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA
  di: Shunsuke Yamada, et al.
  Pubblicazione: (2024)
• Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide
  di: Norio Itokawa, et al.
  Pubblicazione: (2024)
• Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
  di: Hyunjae Shin, et al.
  Pubblicazione: (2024)
• Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy
  di: Takahiro Nakashima, et al.
  Pubblicazione: (2024)
• Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
  di: Takanori Suzuki, et al.
  Pubblicazione: (2024)